Traws Pharma reports 80% ORR, 50% CR for rigosertib in RDEB-SCC Phase 2 study

Traws Pharma, Inc.

Rigosertib Phase 2 ISS in RDEB-SCC showed 80% overall response rate (ORR) with 50% complete responses (CR) in evaluable patients.
Results published on June 3, 2025; study enrolled patients who failed prior immune checkpoint inhibitor therapy.
Company also posted corporate presentations for rigosertib and narazaciclib; narazaciclib trials are on hold pending funding.
Traws seeking partnership opportunities for rigosertib in RDEB-SCC, a high unmet need with no approved treatments.
Clinical safety database for rigosertib includes >1,300 patients across prior cancer studies.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.